Principal Investigator - Dr. Joseph Makhema MB.ChB, FRCP

Study Objectives 

Primary Objectives

• To generate standardized datasets characterizing the quality, magnitude, and kinetics of humoral immune responses to SARS-CoV-2 infection in asymptomatic participants and symptomatic participants (both hospitalized and non-hospitalized) experiencing a range of clinical outcomes in order to prepare for similar assessments during trials of immune-based preventive strategies.
• To characterize innate and cellular immune responses to SARS-CoV-2 infection during infection with SARS-CoV-2 in asymptomatic and acutely symptomatic participants (both hospitalized and non-hospitalized).

Study Design: Prospective cohort study

Study Population: Volunteers aged 18 or older

Study Size: Approximately 800 volunteers

Study Duration: 8 months (includes enrollment) with possible extension in response to evolving information regarding SARS-CoV-2 infection and COVID-19.

Sponsors:

• Division of AIDS (DAIDS)
• National Institute of Allergy and Infectious Diseases (NIAID)
• National Institutes of Health (NIH)
• Department of Health and Human Services (DHHS) Bethesda, Maryland, USA